Registration is now open for Tribe Public’s upcoming CEO Presentation and Q&A Webinar Event featuring GeoVax Labs, Inc. (Nasdaq: GOVX) Chairman & CEO David Dodd. The webinar, titled “Ebola, Marburg, Hantavirus, Mpox and Beyond: Building a Resilient Infectious Disease Preparedness Strategy,” is scheduled for Thursday, May 28, 2026, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. The event will focus on the need for platform-based vaccine technologies to address multiple emerging viral threats.
David Dodd emphasized the limitations of current single-threat approaches, stating, “Ebola, Marburg, Mpox and most recently Hantavirus concerns all reinforce the same lesson: global preparedness strategies must evolve beyond reactive, single-threat approaches.” He highlighted that GeoVax is advancing versatile MVA-based vaccine technologies designed to support broader infectious disease preparedness and address critical gaps in domestic and global biodefense infrastructure.
The webinar discussion is expected to cover the growing importance of platform-based vaccine technologies, why emerging outbreaks continue to expose vulnerabilities in global response infrastructure, the potential applicability of MVA-based technologies across multiple viral threats including orthopox and hemorrhagic fever viruses, and the importance of scalable and resilient domestic vaccine manufacturing capabilities.
GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. This webinar provides an opportunity for investors and stakeholders to learn about GeoVax’s strategy and the potential role of its technology in strengthening pandemic preparedness.
To register for the complimentary Zoom webinar event, visit Ebola-May-2026.TribePublic.com. Once registered, participants may begin submitting questions for GeoVax management to Tribe Public at research@tribepublic.com or submit questions during the live webinar using Zoom’s chat feature. Tribe Public Managing Member John F. Heerdink, Jr. will host the event and moderate audience questions.
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. In oncology, the company is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer. GeoVax maintains a global intellectual property portfolio and continues to evaluate strategic partnerships and funding opportunities.
Tribe Public LLC, headquartered in San Francisco, California, facilitates corporate-sponsored global webinars and investor engagement events focused on emerging companies, technologies, and market opportunities. Its membership community includes family offices, portfolio managers, accredited investors, analysts, and media professionals.
The implications of this webinar are significant for the biodefense and infectious disease preparedness sectors. As recent outbreaks of Ebola, Marburg, Mpox, and Hantavirus have demonstrated, the world remains vulnerable to emerging viral threats. GeoVax’s focus on versatile MVA-based platform technology could provide a more agile response capability, potentially reducing the time and cost associated with developing vaccines for new pathogens. For investors and industry observers, the webinar offers insights into how platform technologies might reshape global health security strategies.
